 | • レポートコード：MRC2203A077 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界のがんバイオマーカー市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、疾患別（前立腺がん、乳がん、肺がん、大腸がん、子宮頸がん）分析、種類別（タンパク質バイオマーカー、遺伝子バイオマーカー、その他）分析、プロファイリング技術別（OMICS技術、画像技術、イムノアッセイ、細胞遺伝）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のがんバイオマーカー市場規模：疾患別（前立腺がん、乳がん、肺がん、大腸がん、子宮頸がん） ・世界のがんバイオマーカー市場規模：種類別（タンパク質バイオマーカー、遺伝子バイオマーカー、その他） ・世界のがんバイオマーカー市場規模：プロファイリング技術別（OMICS技術、画像技術、イムノアッセイ、細胞遺伝） ・世界のがんバイオマーカー市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（23andMe、Abbott Laboratories Inc.、Agilent Technologies、…） ・市場機会・将来傾向 |
The cancer biomarkers market is expected to register a CAGR of nearly 13.1% during the forecast period. Certain factors that are driving the market growth include the increased incidence of cancer, globally, and higher acceptance of treatments for cancer in the developing regions, the paradigm shift in healthcare, from disease diagnosis to risk assessment or early diagnosis, and increasing usage of biomarkers in drug development.
According to the World Health Organization (WHO) 2018 report, cancer is the second leading cause of death worldwide and is responsible for an estimated 9.6 million deaths in the year 2018. Globally, about 1 in 6 deaths is due to cancer. About 70% of deaths from cancer occur in low- and middle-income countries. Additionally, the increased burden of several lifestyle disorders is also expected to drive the market, as biomarkers play a vital role in risk assessment, early diagnosis, and effective monitoring of treatment.
As data is being generated aggressively in the healthcare sector, a few developing countries have surpassed the lack of data, and it is likely to become so in the remaining countries as well. This augmentation of data is expected to provide the basis for any national policy on cancer. In turn, this factor may possibly lead to an increase in the percentage of people opting for cancer treatment. Thus, the increase in demand in the low- and middle-income countries is projected to boost the cancer biomarkers market.
Key Market Trends
Lung Cancer Segment is Expected to Hold a Major Market Share in the Cancer Biomarkers Market
Lung cancer is the second most common type of cancer and the leading cause of death worldwide (caused by any type of cancer) among men and women, as per the 2018 statistics published by the American Society of Clinical Oncology.
Lung cancer is caused by the uncontrolled growth of abnormal cells that multiply in one lung or both lungs. Although it can affect people who never smoked, people who smoke have the highest risk of lung cancer. The risk of lung cancer increases with the duration and number of cigarettes that the patient smoked. Other risk factors include occupational or environmental exposure to secondhand smoke, asbestos, certain metals, some organic chemicals, radiation, air pollution, and diesel exhaust.
The primary factors driving the growth of this segment is the rising prevalence and incidence of lung cancer. According to GLOBOCAN, in 2018, 2,093,876 new cases of lung cancer were reported, globally. Some of the biomarkers for lung cancer include CYFRA 21-1, Plasma Kallikrein (KLKB1), Serum Amyloid A (SAA), Haptoglobin β Chain (Hp β), Complement Component 9 (C9), Endoglin (CD105), Peroxiredoxin 1 (PRX1), and Pro-gastrin-releasing Peptide (proGRP).
Moreover, with such a high incidence rate of lung cancer across the world, the demand for diagnostic devices is sure to rise, in turn, leading to the growth of this segment in the years to come.
North America Dominates the Market and is Expected to do the Same Over the Forecast Period
The United States witnessed a considerable rise in the number of cancer patients. According to the estimates of the American Cancer Society, in 2018, in the United States, 1,735,350 new cancer cases were diagnosed and 609,640 deaths occurred due to cancer. The most common cancers in the United States are breast cancer, lung cancer, prostate cancer, colorectum cancer, bladder cancer, and skin cancer.
The ease in the United States government regulations and availability of funds from various organizations, like the National Institute of Health, has provided the potential for researchers to invest more in the use of biomarkers in drug discovery, drug development, detection of specific tumours, monitoring biological response to cancer therapy, and genetic studies for the identification of predisposed candidates of cancer.
Competitive Landscape
The cancer biomarkers market is highly competitive and consists of a few major players. Some of the companies which are currently dominating the market are 23andMe, Abbott Laboratories Inc., Agilent Technologies, Ambry Genetics, Biomerieux, Celera Corporation (Quest Diagnostics), F. Hoffmann-La Roche Ltd, Hologic Inc., Illumina Inc., and Thermo Fisher Scientific, among others, hold substantial shares in the market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Burden of Cancer, Globally, and Higher Acceptance for Treatment in the Developing Regions
4.2.2 Paradigm Shift in Healthcare from Disease Diagnosis to Risk Assessment or Early Diagnosis
4.2.3 Increasing Focus on Innovative Drug Development
4.3 Market Restraints
4.3.1 High Cost of Diagnosis
4.3.2 Reimbursement Issues
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Disease
5.1.1 Prostate Cancer
5.1.2 Breast Cancer
5.1.3 Lung Cancer
5.1.4 Colorectal Cancer
5.1.5 Cervical Cancer
5.1.6 Other Diseases
5.2 By Type
5.2.1 Protein Biomarkers
5.2.2 Genetic Biomarkers
5.2.3 Other Types
5.3 By Profiling Technology
5.3.1 OMICS Technology
5.3.2 Imaging Technology
5.3.3 Immunoassays
5.3.4 Cytogenetics
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 23andMe
6.1.2 Abbott Laboratories Inc.
6.1.3 Agilent Technologies
6.1.4 Ambry Genetics (Konica Minolta Inc.)
6.1.5 Biomerieux
6.1.6 Quest Diagnostics
6.1.7 F. Hoffmann-La Roche Ltd
6.1.8 Hologic Inc.
6.1.9 Illumina Inc.
6.1.10 Thermo Fisher Scientific
7 MARKET OPPORTUNITIES AND FUTURE TRENDS